Viewing Study NCT06177301



Ignite Creation Date: 2024-05-06 @ 7:54 PM
Last Modification Date: 2024-10-26 @ 3:16 PM
Study NCT ID: NCT06177301
Status: RECRUITING
Last Update Posted: 2024-01-17
First Post: 2023-12-11

Brief Title: Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of RM NPC
Sponsor: Fudan University
Organization: Fudan University

Study Overview

Official Title: A Phase III Clinical Study of Tislelizumab Combined With GX Regimen Versus Tislelizumab Combined With GP Regimen in the First-line Treatment of Recurrence or Metastasis RM Nasopharyngeal Carcinoma NPC
Status: RECRUITING
Status Verified Date: 2024-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None